Ebola vaccine set for trial in West Africa
- quillmastersslcj
- Jan 25, 2015
- 1 min read
The first batch of experimental Ebola vaccine were dispatched to worst affected countries in West Africa where it will be used in a large- scale trials in the coming weeks.
Health care officials who attend to Ebola patients are hoping to distribute the vaccine among them when the trials start. Researchers hope to eventually enroll up to 30,000 people in the trials.
The vaccine, co-developed by the National Institute of Health in the United States and Okairos, a biotechnology firm acquired by UK drug maker GlaxoSmithKline (GSK) in 2013, is now being tested in safety trials in Britain, the US, Switzerland and Mali.
The vaccine uses a type of chimpanzee cold virus to deliver safe genetic material from the Zaire strain of Ebola, the strain responsible for the unprecedented West African epidemic.
Data show the vaccine is safe in people, including in a West African population and in a range of dose levels, GSK said.
by Hafsa Sabry
コメント